Lundbeck of Denmark, the world’s No.1 neurological pharmaceutical company chose to set up its first Asian factory in Tianjin after selling drugs in China for 16 years. It’s another global strategy for Lundbeck, targeting China after the company established a research and development center in Shanghai in 2010. The first phase of investment in this project would be about €6 million, mainly for the production of Ebixa, a drug for treating Alzheimer’s disease. Lundbeck has obtained the production license for Ebixa and will officially put it into production in the second quarter of 2013. Lundbeck also plans to introduce the antidepressant Deanxit, and other drugs related to conditions of the central nervous system over the next three years. “China, with the biggest growing potential, is an important market for Lundbeck’s global strategy,” said Herman Santoni, president and general manager of Lundbeck China.
